ZVRA
Zevra·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ZVRA
Zevra Therapeutics, Inc.
A specialty pharmaceutical company focused on treatments for rare central nervous system, neurodegenerative and lysosomal storage diseases
1180 Celebration Boulevard, Suite 103, Celebration, FL 34747
--
Zevra Therapeutics, Inc., was incorporated in Iowa in October 2006 and reorganized in Delaware in May 2014. The company is a rare disease company that combines science, data and patient needs to create translational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapies to people with rare diseases. With a unique, data-driven development and commercialization strategy, the company is overcoming complex drug development challenges to deliver new therapies to the rare disease community. The company has a diverse product portfolio and product candidates that include preclinical development programs, clinical-stage pipelines and commercial-stage assets. The company's team has expertise and a successful track record of advancing promising therapies that face complex clinical and regulatory challenges by balancing science and data with patient needs.
Earnings Call
Q1/2025
Estimate EPS-0.18
Actual EPS-0.06
Estimate Revenue16.96M
Actual Revenue20.40M
MIPLYFFA's Q1 2025 Earnings Call: Contradictions Unveiled in Patient Enrollment and Reimbursement Challenges
May 20,2025 01:10
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS1.27
Actual EPS-0.06
Estimate Revenue22.49M
Actual Revenue25.90M
Zevra Therapeutics' Q2 2025 Earnings Call: Unraveling Contradictions in Patient Enrollment Strategies and Reimbursement Timelines
Aug 12,2025 10:27
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ZVRA has released its 2025 Q3 earnings. EPS was reported at -0.01, versus the expected -0.07, beating expectations. The chart below visualizes how ZVRA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ZVRA has released its 2025 Q3 earnings report, with revenue of 26.06M, reflecting a YoY change of 605.36%, and net profit of -544.00K, showing a YoY change of 98.36%. The Sankey diagram below clearly presents ZVRA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
